A02西藥製劑(新藥開發)、C06再生醫療(細胞治療、基因治療、組織工程等)

AdipoSeeds invented a novel technology of making platelets from mesenchymal stem cells with a simple manufacturing process and avoids complex and costly gene transfer. With this technology, making platelets from fat tissue is now possible. AdipoSeeds aims to solve the shortage of platelets in the world due to aging society, and to create a future where platelet-related treatments are affordable and safe.

AdipoSeeds, Inc. is a Japanese biotechnology company specializing in allogenic regenerative medicine using human Adipose-derived mesenchymal Stem Cell Line - derived Platelet Like Cells (ASCL-PLC). We are now focusing the development of our two lead asset. (1) ADS-01 is expected to have therapeutic effect by dropping the product onto wound surface for patients who suffer from intractable skin ulcer as the existing therapy (wound dressing, intervention for blood vessel, growth-factor product, prostaglandin product, negative pressure wound therapy, etc.) is not effective. We have already had First-in-Human data. (2) ADS-02 has some advantages for platelet transfusion such as stable and systematic supply, longer shelf life, safety, etc., and can solve problems related to the shortage of platelet products in clinical environments.